In addition, the management of dyslipidemia in patients with diabetes and metobolic syndrome is addressed, and the differences between the old and new guidelines are highlighted. The ATP III ...

[3] The HMG-CoA reductase inhibitors work by inhibiting a key step in hepatic cholesterol synthesis, leading to decreased levels of total cholesterol. Decreased total cholesterol may lead to an ...

Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities. Lipids are a type of fat that make up the ...